Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04665050
Status:
COMPLETED
Last Update Posted:
2023-10-04
First Post:
2020-12-08
Brief Title:
Safety Tolerability and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine V116 in Japanese Adults V116-002
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase 1 Randomized Double-blind Active-Comparator-controlled Study to Evaluate the Safety Tolerability and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety tolerability and immunogenicity of a polyvalent pneumococcal conjugate vaccine V116 with that of PNEUMOVAX23 in healthy Japanese adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| pPCV-002 | OTHER | None | None |
| jRCT2071200094 | REGISTRY | None | None |
| V116-002 | OTHER | Merck | None |